Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:11:05 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:AGIO - AGIOS PHARMACEUTICALS INC - https://www.agios.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AGIO - Q0.122.23·60.000.126.53-0.04-0.21,150.229,97010,73227.03  27.425  26.5045.99  22.2419:51:59Jan 2615 min RT 2¢

Recent Trades - Last 10 of 10732
Time ETExPriceChangeVolume
19:51:59Q27.060.4910
18:12:09Q27.060.493
17:15:26Q26.590.0210
17:14:53Q26.700.1310
16:41:46Q26.53-0.04147
16:10:04Q26.53-0.041
16:06:09Q26.53-0.04139
16:04:40Q26.53-0.041
16:04:22Q26.53-0.041
16:04:16Q26.53-0.041

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-26 07:00U:AGIONews ReleaseAgios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET
2026-01-12 07:00U:AGIONews ReleaseAgios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
2026-01-05 07:00U:AGIONews ReleaseAgios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
2025-12-23 19:45U:AGIONews ReleaseU.S. FDA Approves Agios' AQVESME(TM) (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
2025-12-08 07:00U:AGIONews ReleaseAgios Provides Update on U.S. sNDA for Mitapivat in Thalassemia
2025-11-19 07:00U:AGIONews ReleaseAgios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
2025-11-03 09:01U:AGIONews ReleaseAgios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
2025-10-30 06:30U:AGIONews ReleaseAgios Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-10-17 08:01U:AGIONews ReleaseAgios' PYRUKYND(TM) (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
2025-10-16 07:00U:AGIONews ReleaseAgios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET
2025-09-04 07:00U:AGIONews ReleaseAgios Provides Update on U.S. PDUFA Goal Date for PYRUKYND(TM) (mitapivat) in Thalassemia
2025-08-04 16:01U:AGIONews ReleaseAgios' PYRUKYND(TM) (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
2025-07-31 06:30U:AGIONews ReleaseAgios Reports Second Quarter 2025 Financial Results and Provides Business Update
2025-07-14 07:00U:AGIONews ReleaseAgios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET
2025-07-08 07:00U:AGIONews ReleaseAgios Appoints Dr. Jay Backstrom to Board of Directors
2025-05-28 07:00U:AGIONews ReleaseAgios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
2025-05-14 10:00U:AGIONews ReleaseAgios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
2025-05-09 07:00U:AGIONews ReleaseAgios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
2025-05-02 07:00U:AGIONews ReleaseAgios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025
2025-05-01 06:30U:AGIONews ReleaseAgios Reports First Quarter 2025 Financial Results and Recent Business Highlights